Related Experiment Video
Updated: May 11, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Combination therapy for psoriasis in the United States
Scott A Davis1, Steven R Feldman
1Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Journal of Drugs in Dermatology : JDD
|May 9, 2013
Summary
Combination therapy is common for psoriasis treatment in the U.S. Topical steroids combined with other topicals or vitamin D analogues were most frequent, with increasing use of vitamin D analogues and systemic treatments over time.
Area of Science:
- Dermatology
- Pharmacology
- Health Services Research
Background:
- Psoriasis treatment frequently involves combination therapies, but their specific utilization patterns are not well-documented.
- Understanding combination therapy use is crucial for optimizing psoriasis management.
Purpose of the Study:
- To analyze the prescribing frequency of calcipotriene and other psoriasis medications in combination.
- To characterize the landscape of combination psoriasis pharmacotherapy.
Main Methods:
- Analysis of National Ambulatory Medical Care Survey data from 1990-2010, focusing on psoriasis visits.
- Examination of the number and types of combination therapies prescribed, including leading agents and common pairings.
Main Results:
- Over 10 million psoriasis visits involved combination therapy, with the average number of prescribed medications increasing significantly over time (P=.0003).
- Common combinations included topical steroid with other topicals (15.0%), multiple topical steroids (11.5%), topical steroid with vitamin D analogue (9.7%), and topical steroid with systemic treatment (6.9%).
- Prescribing of vitamin D analogues and systemic treatments increased, while topical steroid use decreased, and other topical use remained stable.
Conclusions:
- Combination therapy is the predominant approach for psoriasis management in the United States.
- The diversity in combination therapies suggests a trend towards personalized treatment strategies tailored to individual patient needs and preferences.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.